AIM: To evaluate the effect of pyrrolidine dithio-carbamate (PDTC; an NF-kappaB inhibitor) administered at low (50 mg/kg) and high (100 mg/kg) doses in suppressing colitis in mice with dextran sodium sulfate (DSS)-induced colitis. METHODS: Mice were divided into a DSS-untreated group (normal group), DSS-treated control group, DSS+PDTC-treated group I (low-dose group), and DSS+PDTC-treated group II (high-dose group). In each group, the disease activity index score (DAI score), intestinal length, histological score, and the levels of activated NF-kappaB and inflammatory cytokines (IL-1beta and TNF-alpha) in tissue were measured. RESULTS: The DSS+PDTC-treated group II exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-kappaB level and IL-1beta and TNF-alpha levels were significantly lower in DSS+PDTC-treated group II. CONCLUSION: These findings suggest that PDTC is useful for the treatment of ulcerative colitis.
AIM: To evaluate the effect of pyrrolidine dithio-carbamate (PDTC; an NF-kappaB inhibitor) administered at low (50 mg/kg) and high (100 mg/kg) doses in suppressing colitis in mice with dextran sodium sulfate (DSS)-induced colitis. METHODS:Mice were divided into a DSS-untreated group (normal group), DSS-treated control group, DSS+PDTC-treated group I (low-dose group), and DSS+PDTC-treated group II (high-dose group). In each group, the disease activity index score (DAI score), intestinal length, histological score, and the levels of activated NF-kappaB and inflammatory cytokines (IL-1beta and TNF-alpha) in tissue were measured. RESULTS: The DSS+PDTC-treated group II exhibited suppression of shortening of intestinal length and reduction of DAI score. Activated NF-kappaB level and IL-1beta and TNF-alpha levels were significantly lower in DSS+PDTC-treated group II. CONCLUSION: These findings suggest that PDTC is useful for the treatment of ulcerative colitis.
Authors: Salvatore Cuzzocrea; Prabal K Chatterjee; Emanuela Mazzon; Laura Dugo; Ivana Serraino; Domenico Britti; Giuseppe Mazzullo; Achille P Caputi; Christoph Thiemermann Journal: Br J Pharmacol Date: 2002-01 Impact factor: 8.739
Authors: Stewart M Long; Victor E Laubach; Curtis G Tribble; Aditya K Kaza; Steven M Fiser; David C Cassada; John A Kern; Irving L Kron Journal: J Surg Res Date: 2003-06-01 Impact factor: 2.192
Authors: Douglas J Kominsky; Simon Keely; Christopher F MacManus; Louise E Glover; Melanie Scully; Colm B Collins; Brittelle E Bowers; Eric L Campbell; Sean P Colgan Journal: J Immunol Date: 2011-04-22 Impact factor: 5.422
Authors: Ahmed M Kabel; Aliaa Atef; Hany M Borg; Azza A K El-Sheikh; Hana J Al Khabbaz; Hany H Arab; Remon S Estfanous Journal: Pharmaceuticals (Basel) Date: 2022-05-13